Following informed consent/consultee declaration,a member of the research will collect relevant clinical and demographic information from the participant and their clinical notes (e.g. age,gender,ethnicity,highest level of education,clinical diagnosis,month and year of stroke,previous strokes (yes/no),cognitive status). These will be recorded on the Trial Entry Form. Participants contact details and preferred mode of contact will also be recorded in the Trial Entry Form. The Trial Entry Form will be shared with the research team using the Microsoft OneDrive server link hosted by ...

GO TO STUDY

The overall aim of this study is to elucidate the molecular and cellular mechanisms underlying RSV-induced lung remodelling that contributes to the development of chronic lung disease such as asthma. This can be split into three objectives: 1. Comparison of RSV-induced responses in bronchial ALI cultures derived from asthmatic and non-asthmatic paediatric patients. 2. Determining secreted factors from RSV-infected bronchial ALI cultures that drive fibroblast-myofibroblast differentiation and fibrosis. 3. Transcriptomic analysis and comparison of bronchial cells from RSV-infected patients and bronchial ALI cultures from asthmatic ...

GO TO STUDY

Stroke due to intracerebral haemorrhage (ICH) is a devastating cardiovascular disease that causes 48% of disability-adjusted life years due to stroke. ICH survivors are at high risk of further major adverse cardiovascular or cerebrovascular events (MACE, i.e. hospitalisation due to stroke [ischaemic or ICH], hospitalisation due to myocardial infarction, or cardiovascular death [by ischaemia, bleeding or other vascular causes]). In the REstart or STop Antithrombotics Randomised Trial (RESTART) of 537 people with cardiovascular diseases who survived ICH in the UK, ...

GO TO STUDY

Acute ischemic stroke (AIS) is a major cause of disability and mortality worldwide. It is caused by an abrupt blockage of an arterial vessel to the brain that results in focal ischemia. The primary therapeutic goal is rapid blood flow restoration using established treatment strategies such as intravenous thrombolysis (IVT) or endovascular therapy (mechanical retraction of blood clots,[EVT]). Despite major advances in reperfusion therapies since EVT became the standard of care in 2015,up to 40% of patients treated with EVT ...

GO TO STUDY

Maintaining adequate vision for safe driving is a common concern for people with diabetic eye disease. One of the typical treatments for severe levels of diabetic eye disease is panretinal photocoagulation (PRP) laser treatment. Although PRP laser has been shown to halve the risk of severe vision loss and help to stabilise diabetic eye disease in the long term, it causes laser scars that can affect peripheral vision. In addition to visual acuity standards (reading a number plate from 20m), ...

GO TO STUDY

The study will be a pragmatic,Phase IIIb,two-arm,double-blind randomised (1:1) placebo-controlled trial of ASUC patients admitted to UK National Health Service (NHS) hospitals. The study will recruit 300 patients admitted to hospital with suspected ASUC over ~30 months across up to 30 UK sites. Participant involvement in the study will depend on their response to IMP or placebo treatment. Screening,baseline assessment and randomisation will take place within 36 hours from the first dose of IV corticosteroids. The initial blinded IMP or placebo treatment ...

GO TO STUDY

The primary objective of the trial,to determine the proportion of patients in glucocorticoid-free ICI-IA remission 24 weeks from initiation of treatment,will be compared between the treatment arms using either a Chi-Squared or Fisher’s exact test (dependent on distributional assumptions). Moreover,we will use logistic regression models,adjusted for stratification variables and other baseline covariates deemed to be associated with the outcome (such as patient standard of care). This will allow us to present the treatment effect for each stratum of stratification ...

GO TO STUDY

We are testing a drug called ginisortamab that blocks a protein called gremlin-1. Gremlin-1 is mainly found outside cancer cells and stops the function of other proteins called bone morphogenetic proteins (BMPs). BMP proteins work by suppressing cancer cells as they occur but in cancer, this mechanism has often been switched off. Blocking gremlin-1 with ginisortamab will allow BMP protein function, and we hope this will change the way the cancer cells develop, making them more sensitive to chemotherapy. We are testing ginisortamab ...

GO TO STUDY

Research question In patients who have a high-risk primary cutaneous squamous cell carcinoma (HR-cSCC) surgically excised with clear margins,is adjuvant radiotherapy plus close clinical follow-up superior in reducing the risk of loco-regional recurrence compared with close clinical follow-up alone,and if so,is it cost-effective? Background cSCC is the second most common skin cancer in the UK,with annual incidence exceeding 52,000,increasing by 6% p.a (1,2). Treatment,usually surgery,is curative in 95% (3,4). However,5% of patients develop loco-regional recurrence (LRR) which causes 75% of cSCCspecific mortality,substantial morbidity and reduced quality of life (QoL) ...

GO TO STUDY

Myeloma is a treatable, but incurable, malignancy of plasma cells in the bone marrow (BM). It represents the final stage in a continuum of plasma cell disorders (PCDs) and is consistently preceded by a premalignant phase termed monoclonal gammopathy of undetermined significance (MGUS). MGUS therefore provides the opportunity to study how a premalignant condition progresses into cancer. MGUS-to-myeloma progression requires multiple genomic events and establishment of a permissive bone marrow microenvironment (BME). Historically, obtaining patient material to study MGUS has ...

GO TO STUDY